Skip to content

Welcome to Discover Pharma! Today is : November 4, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical & Regulatory

  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    iOnctura to present roginolisib data in immunotherapy-resistant lung cancer

    iOnctura will present late-breaking clinical data on roginolisib in patients [...]

    November 2, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Newron completes Phase 3 trial enrolment in schizophrenia

    Newron Pharmaceuticals has completed enrolment of 618 patients in its [...]

    October 29, 2026
  • Clinical & Regulatory,Digital & Data,Genomics and sequencing,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Personalised cancer medicine: closing the clinical trial access gap

    Personalised cancer medicine is advancing, but better biomarker testing, clinical [...]

    October 29, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Mineralys reports lorundrostat results in hypertension and kidney disease

    Mineralys Therapeutics has reported Phase 3 data showing lorundrostat reduced [...]

    October 27, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    SalubrisBio reports JK06 results across three cancer types

    SalubrisBio has reported Phase 1b/2 results for its investigational antibody-drug [...]

    October 27, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Tango reports 82% response rate in pancreatic cancer trial

    Tango Therapeutics has reported an 82% objective response rate with [...]

    October 27, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    FDA seeks input on new rare disease drug development framework

    The FDA is seeking public feedback on plans to tailor [...]

    October 23, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Cabenuva real-world study reports sustained HIV viral suppression

    A US observational study of nearly 7,000 adults with HIV-1 [...]

    October 23, 2026
  • Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    AmplexDiagnostics launches rapid Candida auris resistance test

    AmplexDiagnostics has launched a CE-IVD molecular diagnostic test that detects [...]

    October 21, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    SeaBeLife secures €2.9m to advance acute liver injury drug

    SeaBeLife has secured €2.9 million in French government funding to [...]

    October 21, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ETH Zurich develops electronic implant to lower blood glucose
    Categories: Digital & Data, Drug Discovery & Development, Medical devices, Research & Development, Therapeutic Areas
  • Mineralys reports lorundrostat results in hypertension and kidney disease
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • SalubrisBio reports JK06 results across three cancer types
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top